SAN DIEGO, July 24 /PRNewswire-FirstCall/ -- Biosite(R) Incorporated today announced the premiere of its third-generation testing platform, the Triage(R) MeterPro(TM), at the American Association for Clinical Chemistry 2006 Annual Meeting, to be held in Chicago from July 23 through 27, 2006. The Triage MeterPro combines Biosite’s rapid, easy-to-use technology with a more convenient user interface. The Triage MeterPro’s user-friendly features will make testing even easier to perform, while maintaining the high quality and performance standards of the existing Triage Meter platform.
(Photo: http://www.newscom.com/cgi-bin/prnh/20060724/LAM077 )
Enhancements to the Triage MeterPro include an alphanumeric keypad, 75 percent larger display, backlighting and faster printing. The Triage Meters also feature “Test Select(TM),” which gives healthcare providers the flexibility to customize test menus based on physician preference or patient presentation when using Triage Test Panels with multiple analytes. This allows customers to use the same multi-analyte Triage Panel but choose which assays to run at the time of testing.
The Triage MeterPro is a portable, rapid testing platform designed to provide rapid, quantitative or qualitative results for immunoassays using urine, whole-blood or plasma and features comprehensive built-in quality control capabilities. Biosite’s current and future Triage tests will continue to be compatible with the Triage MeterPro and the Triage MeterPlus. The Triage MeterPro is now available in the United States and will launch internationally in the second half of 2006.
For information on the Triage MeterPro or how to order Biosite products, please contact Biosite at (888) BIOSITE (246-7483), or email: custservice@biosite.com.
About Biosite Incorporated
Biosite Incorporated is a leading bio-medical company commercializing proteomics discoveries for the advancement of medical diagnosis. The Company’s products contribute to improvements in medical care by aiding physicians in the diagnosis of critical diseases and health conditions. Biosite’s Triage rapid diagnostics are used in approximately 50 percent of U.S. hospitals and in more than 50 international markets. Information on Biosite can be found at www.biosite.com.
Except for the historical information presented herein, matters discussed in this press release are forward-looking statements that involve risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Statements that are not historical facts, including but not limited to statements that are preceded by, followed by, or that include the words “will"; “believes"; “should"; “intends"; “anticipates"; “plans"; “expects"; “estimates"; or similar statements are forward-looking statements. Forward looking statements include statements about the potential benefits of the Triage MeterPro, and the commencement of marketing, education and sales of this third-generation product. Risks and uncertainties include risks regarding the discovery and product development process generally, risks associated with the commencement of manufacturing the Triage MeterPro on a commercial scale and risks that the Triage MeterPro may not be commercially successful. Other risks and uncertainties that may impact the Company’s business generally include risks associated with the introduction of competitive products from companies with greater capital and resources, expansion or development of a direct sales effort in domestic and international markets, manufacturing constraints, backlog, delays or inefficiencies, shipment problems, regulatory changes and the other risks detailed in the Company’s most recent Annual Report on Form 10-K and other SEC filings. The Company disclaims, however, any intent or obligation to update these forward-looking statements. Copies of the Company’s public disclosure filings are available from the Investor Relations department.
Biosite(R), Triage(R) and New Dimensions in Diagnosis(R) are registered trademarks of Biosite Incorporated. The Company’s logo, MeterPro and Test Select are trademarks of Biosite Incorporated.
Photo: NewsCom: http://www.newscom.com/cgi-bin/prnh/20060724/LAM077AP Archive: http://photoarchive.ap.orgPRN Photo Desk, photodesk@prnewswire.comBiosite Incorporated
CONTACT: Nadine Padilla, VP, Corporate & Investor Relations,+1-858-805-2820, npadilla@biosite.com, or Susan Schotthoefer, Sr. CorporateCommunications Specialist, +1-858-805-2804, sschott@biosite.com, both ofBiosite Incorporated
Web site: http://www.biosite.com/
Company News On-Call: http://www.prnewswire.com/comp/116737.html /
